« Myriad Prevails Over "Magic Microscope" in AMP v. USPTO | Main | Pfizer CEO Says He Isn’t ‘Chasing Revenue’ in Big Deals as Patents Expire »



TrackBack URL for this entry:

Listed below are links to weblogs that reference Pharma Mega-Mergers Bad News for R&D Productivity:


Feed You can follow this conversation by subscribing to the comment feed for this post.


Bernard Munos argues in Fierce Biotech article (via Forbes' Matt Herper) that big pharma R&D needs to be radically revamped to regain productivity of past


More commentary on the LaMattina piece from Derek Lowe's In the Pipeline blog

Terry McCormick

This meta-analysis I did earlier this year can be a good complement to John Lamattina's discussion. No clear answers, but maybe some visual signals as to the effects of mergers. http://www.randdreturns.com/in-progress-nmes-vs-mergers/

The effects of mergers has been topical for a looong time. Twenty years ago, the financial professors at Wharton were explaining that many became distractions from the core business (R&D?) and were often "smokescreens to fool stockholders" around a slumping business. I have lived and seen the distractions and effects on Pharma R&D first hand in at least six firms, both as a scientist and as an advisor. Key learning is to keep FOCUSED on what creates and sustains value to the business - and not just short-term.

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC

visited 6 states (46.1%)
Create your own visited map of Canada